Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder

Santos, Rafael G. dos; Osório, Flávia de Lima; Rocha, Juliana Mendes; Rossi, Giordano Novak; Bouso, José Carlos; Rodrigues, Lucas S.; Silveira, Geraldo; Yonamine, Maurı́cio; Hallak, Jaime Eduardo Cecílio

doi:10.1097/jcp.0000000000001428

Cited by 61 publications

(55 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This case involved a brief but intense moment of disorientation and anxiety, which was resolved with verbal management. 16 The last 3 clinical studies carried out by our research group [4][5][6] (including the manuscript in preparation) gathered a total sample of 56 individuals, including 39 healthy and 17 socially anxious volunteers. Of these, 37 received a single dose of ayahuasca, and only 2 individuals reported a PAR (described here).…”

Section: Discussionmentioning

confidence: 99%

“…In the placebo group, somnolence (n = 1) was the only event reported. In the trial with socially anxious individuals, 6 a total of 17 adverse effects were reported. In the ayahuasca group, gastrointestinal discomfort and nausea (n = 4), vomiting (n = 3), drowsiness (n = 2), headache (n = 2), diarrhea (n = 1), confusion (n = 2), fear (n = 1), distress (n = 1), and dissociation/depersonalization (n = 1) were reported (the last 4 effects were described in case 1).…”

Section: Discussionmentioning

confidence: 99%

“…Recently published open-label and randomized clinical trials involving 1 or 2 doses of these substances demonstrated antidepressant, anxiolytic, and antiaddictive effects, with few adverse effects 1–3 . In recent years, our research group has carried out controlled trials involving the administration of a single ayahuasca dose 4–6 . To the best of our knowledge, there is no systematic description in the literature on how to handle psychological adverse reactions (PARs) in clinical trials with ayahuasca.…”

mentioning

confidence: 99%

“…The room was predominantly light-colored, with a wood desk, and components used for data collection (eg, blood collection equipment, notebook). No specific psychotherapeutic intervention was used before, during, or after the experiments, as in our previous studies 6–8 . Our protocol included general principles described in recent guidelines for safety in human hallucinogen research 9 .…”

mentioning

confidence: 99%

“…[1][2][3] In recent years, our research group has carried out controlled trials involving the administration of a single ayahuasca dose. [4][5][6] To the best of our knowledge, there is no systematic description in the literature on how to handle psychological adverse reactions (PARs) in clinical trials with ayahuasca. Thus, this is the first scientific report detailing the management of PARs with ayahuasca in such context.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Adverse Effects After Ayahuasca Administration in the Clinical Setting

Rocha

Rossi

Osório

et al. 2022

J Clin Psychopharmacol

Self Cite

View full text Add to dashboard Cite

and consult an ophthalmologist immediately. Also, according to the literature, drug-associated acute ACG is believed to be idiosyncratic in nature. That is to say that the ocular adverse effects, unlike the systemic ones, are not dose related, 6 as illustrated in this case report-our patient received only 100 mg of topiramate per day, whereas the recommended clinical dose for approved indications is 200 to 400 mg daily. Supporting its idiosyncratic nature, 3 different reasons can be pointed out: (1) a very small proportion of the patients who are under topiramate treatment develop drug-associated bilateral ACG; (2) low or even subtherapeutic levels of the drug can be associated with the condition;(3) there are cases of topiramate overdose that did not result in bilateral ACG development. 7 Delaying the presentation or continuing the drug can lead to permanent blindness or compromise the quality of vision for life.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Adverse Effects After Ayahuasca Administration in the Clinical Setting

Rocha

Rossi

Osório

et al. 2022

J Clin Psychopharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof‐of‐concept, randomized, placebo‐controlled trials

Santos

Rocha

Rossi

et al. 2022

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

Objective: To assess endocannabinoid (anandamide, AEA; 2-arachidonoylglycerol, 2-AG) plasma levels in healthy volunteers and in volunteers with social anxiety disorder (SAD) after a single oral dose of ayahuasca or placebo. Methods:Post hoc analysis of endocannabinoid plasma levels (baseline, 90 and 240 min after drug intake) from two parallel-group, randomized, placebo-controlled trials. In Study 1, 20 healthy volunteers ingested ayahuasca (average 1.58 mg/ml dimethyltryptamine (DMT)) or placebo, and in Study 2, 17 volunteers with SAD received ayahuasca (average 0.680 mg/ml DMT) or placebo.Results: A significant difference was observed in AEA concentrations in Study 2 after ayahuasca intake (Χ 2 (2) = 6.5, p = 0.03, Friedman test), and near significant differences (increases) were observed between baseline and 90 (Z = 0, p = 0.06, Wilcoxon test) and 240 (Z = 10, p = 0.06) minutes after ayahuasca intake. Conclusions:Although our findings suggest that ayahuasca could modulate AEA levels in SAD patients, the high interindividual variability in both trials and the small samples preclude definitive conclusions. More research with larger samples is needed to better understand the effects of ayahuasca and other hallucinogens in the endocannabinoid system.

show abstract

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects

Ruffell,

Crosland‐Wood,

Palmer

et al. 2023

PCN Reports

View full text Add to dashboard Cite

Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis. Here we review the history of ayahuasca and describe recent work on its pharmacology, phenomenological responses, and clinical applications. There has been a significant increase in interest in ayahuasca since the turn of the millennium. Anecdotal evidence varies significantly, ranging from evangelical accounts to horror stories involving physical and psychological harm. The effects of the brew on personality and mental health outcomes are discussed in this review. Furthermore, phenomenological analyses of the ayahuasca experience are explored. Ayahuasca is a promising psychedelic agent that warrants greater empirical attention regarding its basic neurochemical mechanisms of action and potential therapeutic application.

show abstract

Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder

Abstract: Supplemental digital content is available in the text.

Cited by 61 publications

References 51 publications

Adverse Effects After Ayahuasca Administration in the Clinical Setting

Adverse Effects After Ayahuasca Administration in the Clinical Setting

Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof‐of‐concept, randomized, placebo‐controlled trials

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects

Contact Info

Product

Resources

About